HyperBranch Medical Technology is a privately-held company based in Durham, N.C. The company is focused on the development of unique products based on its novel hydrogel technology.

October 1, 2018 - Stryker (SYK) announced today the acquisition of privately-held HyperBranch Medical Technology, Inc. for a total equity value of approximately $220 million in an all cash ...

HyperBranch Medical Technology Inc., Raleigh, N.C., raised $6 million in its first round of funding. The round was led by The Aurora Funds, and included H.I.G. Ventures. The funding will be used ...

HyperBranch intends to file a motion pursuant to 35 U.S.C. Section 285 asking the Court to deem the case to be exceptional and award HyperBranch its attorneys’ fees and other defense costs.

HyperBranch has already commercialized a liquid eye bandage called OcuSeal. That product was licensed to medical device giant BD (NYSE:BDX), which is marketing the product outside the United States.

Stryker Corporation SYK recently announced the acquisition of HyperBranch Medical Technology for a deal value of $220 million in cash. The buyout is likely to boost Stryker's core Neurotechnology ...

Stryker Corp. on Monday said it acquired venture-backed medical-device maker HyperBranch Medical Technology Inc. in an all-cash deal valued at about $220 million.

DURHAM, N.C. — HyperBranch Medical Technology, Inc. announced today that on June 8, 2018, after a two-week trial in federal district court in Wilmington, Delaware, an 8-member jury found in favor of ...

HyperBranch Medical Technology has closed on $2 million in new financing.The venture-backed company disclosed the funding in a filing with the Securities and Exchange Commission.HyperBranch said ...

Venture-backed HyperBranch Medical Technology has received approval to sell its liquid ocular bandages in the European Union.The approval enables HyperBranch to formally launch its first product ...

HyperBranch employs 12. The privately held company was founded in 2003. The company has raised $8 million from venture capitalists to develop its product line.